top of page

Our Vision

To provide quality testing solutions that equip clinical providers with the tools to rapidly and efficiently diagnose Valley fever.

Our Mission

To provide high quality tests and reagents for Valley fever in formats that enable rapid testing for patients with answers in minutes, not days or weeks.

Our Story

Cactus Bio emerged from the collaborative research efforts of Dr. Douglas Lake at ASU and Dr. Thomas Grys at Mayo Clinic in Arizona, and is situated within the Health Futures Center (HFC).

In 2012, Drs. Lake and Grys discovered a common interest in seeking better diagnostic tools for valley fever. They were able to fuse their expertise of basic science and clinical diagnostics to establish a track record of funding that led to multiple publications and patents.

 

Dr. Lake has worked in the Valley Fever area for over 20 years primarily exploring the peculiar immunology of the disease (i.e., when antibody titers are increasing, patients are usually getting sicker, and dendritic cell reversal of Coccidioidal anergy). Dr. Grys is board-certified in Clinical Microbiology and has nearly 20 years of experience in the field. He is a director of the hospital laboratory at Mayo Clinic in Arizona.

 

Co-founders Lake and Grys boast a history of effective collaboration, securing support from entities such as the Arizona Biomedical Research Commission, NIH, and FDA. These collaborations aimed at developing enhanced diagnostics for Valley Fever laid the groundwork for the establishment of Cactus Bio.

Adding to the team's expertise, Dr. Francisca Grill joined Cactus Bio in August 2023. Bringing industry experience and serving as co-PI with Dr. Lake on a Phase I Small Business and Innovative Research NIH grant, Dr. Grill's background includes prior employment at IDEXX, a multinational veterinary diagnostics company. Her experience in the diagnostic testing laboratory at IDEXX provided valuable insights into the challenges associated with Valley Fever diagnostics.

About Us Founding Image.jpg

Publications

Development of a rapid lateral flow assay for detection of anti-coccidioidal antibodies.
Grill FJ, Svarovsky S, Gonzalez-Moa M, Kaleta E, Blair JE, Lovato L, Grant R, Ross K, Linnehan BK, Meegan J, Reilly KS, Brown A, Williams S, Chung Y, Magee DM, Grys TE, Lake DF.   /   J Clin Microbiol. 2023 Sep 21;61(9):e0063123. doi: 10.1128/jcm.00631-23. Epub 2023 Sep 1.   /   PMID: 37655868
Clinical Laboratory Utility of a Humanized Antibody in Commercially Available Enzyme Immunoassays for Coccidioidomycosis.
Grill FJ, Jugler C, Kaleta E, Chen Q, Magee DM, Grys TE, Lake DF.   /   Microbiol Spectr. 2022 Oct 26;10(5):e0257322. doi: 10.1128/spectrum.02573-22. Epub 2022 Sep 19.   /   PMID: 36121238
Development of a Quantitative Antigen Assay to Detect Coccidioidal Chitinase-1 (CTS1)
Grill FJ, Grys TE, Grill MF, Roeder A, Blair JE, Lake DF.   /   Open Forum Infect Dis. 2021 Jun 28;8(7):ofab344. doi: 10.1093/ofid/ofab344. eCollection 2021 Jul.   /   PMID: 34337097
Proteogenomic Re-Annotation of Coccidioides posadasii Strain Silveira.
Mitchell NM, Sherrard AL, Dasari S, Magee DM, Grys TE, Lake DF.   /.  Proteomics. 2018 Jan;18(1). doi: 10.1002/pmic.201700173. Epub 2017 Dec 14.   /.  PMID: 29130603

Send us an Inquiry

Thanks for submitting! A representative will be in touch shortly.

bottom of page